6 days Ago By Defense World Staff
Eli Lilly and Company (NYSE:LLY – Free Report) had its target price lowered by Guggenheim from $973.00 to $928.00 in a research note released on Monday morning,Benzinga reports.
The brokerage currently has a buy rating on the stock.LLY has been the subject of a number of other reports. StockNews.
com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $892.00 to $888.
00 in a research report on Tuesday, April 8th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th.
Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th.
Finally, Morgan Stanley lowered their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th.
Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,012.00.
View Our Latest Stock Analysis on Eli Lilly and CompanyEli Lilly and Company Trading Up 2.9 %LLY stock opened at $753.54 on Monday.
The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.
00. The firm has a market cap of $714.48 billion, a P/E ratio of 64.
35, a P/E/G ratio of 1.40 and a beta of 0.51.
Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.
The business’s 50 day moving average is $835.24 and its 200-day moving average is $822.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.
45 by ($0.13). Eli Lilly and Company had a return on equity of 85.
24% and a net margin of 23.51%. Equities analysts anticipate that Eli Lilly and Company will post 23.
48 earnings per share for the current fiscal year. Insider Transactions at Eli Lilly and CompanyIn related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th.
The shares were sold at an average price of $818.24, for a total transaction of $818,240.00.
Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.
62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.
13% of the company’s stock. Institutional Inflows and OutflowsA number of institutional investors and hedge funds have recently made changes to their positions in the business. FWG Holdings LLC raised its holdings in Eli Lilly and Company by 0.
6% in the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company’s stock valued at $1,640,000 after acquiring an additional 12 shares in the last quarter. Morling Financial Advisors LLC raised its stake in Eli Lilly and Company by 4.
7% in the fourth quarter. Morling Financial Advisors LLC now owns 266 shares of the company’s stock valued at $205,000 after purchasing an additional 12 shares in the last quarter. Prestige Wealth Management Group LLC lifted its position in Eli Lilly and Company by 2.
0% during the fourth quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock worth $468,000 after purchasing an additional 12 shares during the period. Applied Finance Capital Management LLC grew its stake in Eli Lilly and Company by 1.
4% during the fourth quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after buying an additional 12 shares in the last quarter. Finally, Garner Asset Management Corp increased its holdings in Eli Lilly and Company by 2.
3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock valued at $411,000 after buying an additional 12 shares during the period. Institutional investors and hedge funds own 82.
53% of the company’s stock. About Eli Lilly and Company (Get Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further ReadingFive stocks we like better than Eli Lilly and Company3 REITs to Buy and Hold for the Long TermWhy NVIDIA Stock Could Soar Despite Wall Street DowngradesTechnology Stocks Explained: Here’s What to Know About TechTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldWhat is a Stock Market Index and How Do You Use Them?3 Hot New IPOs Defying the 2025 Market Slump.
